Table 3.
Accuracy of models: Validated C-statistics with confidence intervals through model training on 70 % of subjects and testing on 30 %
| Urine Only | Urine + Clinical | Sensitivity (%) | Specificity (%) | |
|---|---|---|---|---|
| All cancer vs. control | 0.795 (0.768-0.823) | 0.810 (0.782-0.838) | 81.4 (77.9-84.9) | 60.0 (56.9-63.1) |
| NSCLC vs. control | 0.804 (0.783-0.825) | 0.809 (0.782-0.836) | 80.0 (76.8-83.2) | 64.7 (60.8-68.6) |
| Adenocarcinoma vs. control | 0.900 (0.879-0.920) | 0.917 (0.899-0.936) | 73.3 (69.1-77.6) | 89.7 (87.6-91.8) |
| Squamous vs. control | 0.821 (0.797-0.847) | 0.821 (0.790-0.853) | 60.0 (55.3-64.7) | 87.9 (84.4-91.4) |
| Stage I vs. control | 0.873 (0.848-0.90) | 0.875 (0.856-0.894) | 49.3 (44.9-53.7) | 92.8 (89.5-96.1) |
| Stage I Adenocarcinoma vs. control | 0.875 (0.843-0.906) | 0.876 (0.846-0.906) | 36.0 (27.7-44.3) | 96.9 (95.2-98.6) |
| Stage I Squamous vs. control | 0.940 (0.925-0.955) | 0.938 (0.923-0.953) | 46.7 (39.4-53.9) | 97.6 (96.5-98.7) |
| Adenocarcinoma vs. Squamous | 0.849 (0.828-0.87) | 0.859 (0.831-0.887) | 84.0 (80.8-87.3) | 72.7 (67.2-78.2) |
| Stage I vs. IV | 0.922 (0.892-0.952) | 0.922 (0.892-0.952) | 92.7 (90.2-95.2) | 68.0 (60.3-75.7) |
| All cancer vs. control (matched) | 0.968 (0.954-0.982) | 0.970 (0.954-0.986) | 95.5 (92.4-98.6) | 88.0 (81.2-94.8) |
| NSCLC vs. control (matched) | 0.977 (0.957-0.997) | 0.987 (0.977-0.997) | 86.7 (83.6-89.8) | 96.0 (92.8-99.2) |